Literature DB >> 24819221

Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol.

I E Obiorah1, V C Jordan.   

Abstract

BACKGROUND AND
PURPOSE: Triphenylethylene (TPE)-like compounds were the first agents to be used in the treatment of metastatic breast cancer in postmenopausal women. Although structurally related to the anti-oestrogen, 4-hydroxytamoxifen, TPEs possess oestrogenic properties in fully oestrogenized breast cancer cells but do not induce apoptosis with short-term treatment in long-term oestrogen-deprived breast cancer cells. This study determined the differential effects of bisphenol, a TPE, on growth and apoptosis based on the modulation of the shape of the ligand-oestrogen receptor complex. EXPERIMENTAL APPROACH: Apoptotic flow cytometric studies were used to evaluate apoptosis over time. Proliferation of the breast cancer cells was assessed using DNA quantification and cell cycle analysis. Real-time PCR was performed to quantify mRNA levels of apoptotic genes. Regulation of cell cycle and apoptotic genes was determined using PCR-based arrays. KEY
RESULTS: Bisphenol induced an up-regulation of cell cycle genes similar to those induced by 17β oestradiol (E2 ). Unlike the changes induced by E2 that occur after 24 h, the apoptosis evoked by bisphenol occurred after 4 days, with quantifiable apoptotic changes noted at 6 days. A prolonged up-regulation of endoplasmic reticulum stress and inflammatory stress response genes was observed with subsequent activation of apoptosis-related genes in the second week of treatment with bisphenol. CONCLUSIONS AND IMPLICATIONS: The bisphenol: ERα complex induces delayed biological effects on the growth and apoptosis of breast cancer cells. Both the shape of the complex and the duration of treatment control the initiation of apoptosis.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  Oestrogen-induced apoptosis; bisphenol; breast cancer

Mesh:

Substances:

Year:  2014        PMID: 24819221      PMCID: PMC4243979          DOI: 10.1111/bph.12762

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

Review 1.  Selective estrogen receptor modulation: concept and consequences in cancer.

Authors:  V Craig Jordan
Journal:  Cancer Cell       Date:  2004-03       Impact factor: 31.743

2.  The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.

Authors:  V Craig Jordan; Ifeyinwa Obiorah; Ping Fan; Helen R Kim; Eric Ariazi; Heather Cunliffe; Hiltrud Brauch
Journal:  Breast       Date:  2011-10       Impact factor: 4.380

3.  Defining the conformation of the estrogen receptor complex that controls estrogen-induced apoptosis in breast cancer.

Authors:  Ifeyinwa Obiorah; Surojeet Sengupta; Ramona Curpan; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2014-03-07       Impact factor: 4.436

4.  Molecular classification of estrogens.

Authors:  V C Jordan; J M Schafer; A S Levenson; H Liu; K M Pease; L A Simons; J W Zapf
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

5.  Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells.

Authors:  S Sengupta; I Obiorah; P Y Maximov; R Curpan; V C Jordan
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

6.  Capacity of type I and II ligands to confer to estrogen receptor alpha an appropriate conformation for the recruitment of coactivators containing a LxxLL motif-Relationship with the regulation of receptor level and ERE-dependent transcription in MCF-7 cells.

Authors:  Sandrine Bourgoin-Voillard; Dominique Gallo; Ioanna Laïos; Anny Cleeren; Latifa El Bali; Yves Jacquot; Denis Nonclercq; Guy Laurent; Jean-Claude Tabet; Guy Leclercq
Journal:  Biochem Pharmacol       Date:  2009-10-29       Impact factor: 5.858

7.  Dual involvement of caspase-4 in inflammatory and ER stress-induced apoptotic responses in human retinal pigment epithelial cells.

Authors:  Zong-Mei Bian; Susan G Elner; Victor M Elner
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-30       Impact factor: 4.799

8.  The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer--survival or death?

Authors:  V Craig Jordan
Journal:  J Clin Oncol       Date:  2008-06-02       Impact factor: 44.544

9.  An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro.

Authors:  M E Lieberman; J Gorski; V C Jordan
Journal:  J Biol Chem       Date:  1983-04-25       Impact factor: 5.157

10.  A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family.

Authors:  S Akira; H Isshiki; T Sugita; O Tanabe; S Kinoshita; Y Nishio; T Nakajima; T Hirano; T Kishimoto
Journal:  EMBO J       Date:  1990-06       Impact factor: 11.598

View more
  11 in total

1.  Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

Authors:  V Craig Jordan; Ramona Curpan; Philipp Y Maximov
Journal:  J Natl Cancer Inst       Date:  2015-04-02       Impact factor: 13.506

2.  Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.

Authors:  V Craig Jordan
Journal:  J Natl Cancer Inst       Date:  2014-09-30       Impact factor: 13.506

3.  Avoiding the bad and enhancing the good of soy supplements in breast cancer.

Authors:  V Craig Jordan
Journal:  J Natl Cancer Inst       Date:  2014-09-04       Impact factor: 13.506

Review 4.  The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer.

Authors:  V Craig Jordan
Journal:  Endocr Relat Cancer       Date:  2014-10-22       Impact factor: 5.678

Review 5.  The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.

Authors:  Ping Fan; Philipp Y Maximov; Ramona F Curpan; Balkees Abderrahman; V Craig Jordan
Journal:  Mol Cell Endocrinol       Date:  2015-06-05       Impact factor: 4.102

6.  Integration of Downstream Signals of Insulin-like Growth Factor-1 Receptor by Endoplasmic Reticulum Stress for Estrogen-Induced Growth or Apoptosis in Breast Cancer Cells.

Authors:  Ping Fan; Heather E Cunliffe; Philipp Y Maximov; Fadeke A Agboke; Russell E McDaniel; Xiaojun Zou; Pilar Ramos; Megan L Russell; V Craig Jordan
Journal:  Mol Cancer Res       Date:  2015-06-26       Impact factor: 5.852

7.  Estrogen-Induced Apoptosis in Breast Cancers Is Phenocopied by Blocking Dephosphorylation of Eukaryotic Initiation Factor 2 Alpha (eIF2α) Protein.

Authors:  Surojeet Sengupta; Catherine M Sevigny; Poulomi Bhattacharya; V Craig Jordan; Robert Clarke
Journal:  Mol Cancer Res       Date:  2019-01-17       Impact factor: 5.852

8.  Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer.

Authors:  Philipp Y Maximov; Balkees Abderrahman; Sean W Fanning; Surojeet Sengupta; Ping Fan; Ramona F Curpan; Daniela Maria Quintana Rincon; Jeffery A Greenland; Shyamala S Rajan; Geoffrey L Greene; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2018-05-08       Impact factor: 4.436

9.  The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells.

Authors:  Philipp Y Maximov; Balkees Abderrahman; Yousef M Hawsawi; Yue Chen; Charles E Foulds; Antrix Jain; Anna Malovannaya; Ping Fan; Ramona F Curpan; Ross Han; Sean W Fanning; Bradley M Broom; Daniela M Quintana Rincon; Jeffery A Greenland; Geoffrey L Greene; V Craig Jordan
Journal:  Mol Pharmacol       Date:  2020-05-03       Impact factor: 4.436

Review 10.  Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team.

Authors:  V Craig Jordan
Journal:  Breast Cancer Res Treat       Date:  2021-08-16       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.